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Introduction
DNA-repair gene mutations have been suspected as
being a predisposing factor in the development of leu-
kemia (Horwitz 1997). Our group identified one of the
first examples of a DNA-repair gene mutation to be
causally linked to childhood hematological malignancies
and neurofibromatosis type I, which involves a homo-
zygous germ-line mutation in the mismatch repair
(MMR) gene MLH1 (Ricciardone et al. 1999; Wang
et al. 1999). Subsequently, homozygous inactivation of
MSH2, another MMR gene, was also found to be
associated with early onset leukemia (Whiteside et al.
2002). It is well known that heterozygous germ-line
mutations in the MMR pathway genes MLH1, MSH2,
PMS2, PMS1, and MSH6 lead to hereditary non-
polyposis colorectal cancer (HNPCC) (Peltomaki 2001).
Thus, tumorigenesis through an ‘‘MMR deficiency
pathway’’ appears to be associated with two different
disease phenotypes which are dependent on the status of
the germ-line mutation: (a) HNPCC when the mutation
is present on only one allele (heterozygous), and
(b) hematological malignancies when the mutation(s)
is present on both alleles (homozygous or compound
heterozygous).
Base excision repair (BER) is another important
DNA-repair pathway and plays a significant role in the
repair of mutations generated by reactive oxygen species
during aerobic metabolism. BER was not linked with
any human genetic disorder until recently, when a
British family in which three siblings affected by multiple
colorectal adenomas and carcinoma was shown to be
compound heterozygous for MYH missense variants
Tyr165Cys (Y165C) andGly382Asp (G382D) (Al-Tassan
et al. 2002). MYH is a homologue of E. coli mutY, and
the mutations mentioned above affect residues that are
conserved (Tyr82 and Gly253). Tyrosine 82 is predicted
to function in mismatch specificity and is located in the
pseudo-helix-hairpin-helix (Guan et al. 1998). Adenine
glycosylase activity assays of the Tyr82Cys and
Gly253Asp mutant proteins with 8-oxoG:A and G:A
substrates show that their rate for adenine removal at
37C is reduced by approximately 98% (Tyr82Cys) and
86% (Gly253Asp) (Al-Tassan et al. 2002). Furthermore,
bi-allelic germ-line mutations in MYH were identified in
seven unrelated patients with colorectal adenomas (six
with colorectal cancer) (Jones et al. 2002). Interestingly,
the missense variations Tyr165Cys and Gly382Asp,
which significantly reduce the adenine glycosylase
activity of MYH protein, were each identified once in a
normal control group of 100 British individuals with no
history of colorectal adenoma or carcinoma (Al-Tassan
et al. 2002). Since a connection between DNA-repair
gene mutations and the path to hematological malig-
nancy is now well established, and individuals who carry
heterozygous MYH missense mutations Tyr165Cys and
Gly382Asp have been documented in a control group
(Al-Tassan et al. 2002), we investigated the association
between these two MYH missense mutations and
childhood leukemia risk.
Results and discussion
The study population included 185 cases of childhood
leukemias subdivided into two groups: acute myeloid
leukemia (AML; n=45) and acute lymphoblastic leu-
kemia (ALL; n=140) diagnosed at Istanbul University
between 1998 and 2002. Detailed clinical data are
available for all patients. The French–American–British
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Cooperative Study Group criteria were used for histo-
logical subgroup classification (Cheson et al. 1990).
Randomly selected Bilkent University students, with no
history of hematological malignancies or any other type
of cancer (n=124), were genotyped in order for us to
assess the status of the MYH mutations in apparently
healthy Turkish individuals. Informed consent was
obtained from all the students.
We screened for the MYH Tyr165Cys and Gly382-
Asp variants using genomic DNA as described
(Al-Tassan et al. 2002). Neither mutation was present in
any of the samples, except for that of one patient diag-
nosed with AML/M3. MYH Tyr165Cys mutation in the
heterozygous state was present in the sample obtained at
the time of initial diagnosis. Further sampling at
remission, and the analysis of parental DNA, showed
only the normal allele. Therefore, the mutation was
considered to be specific for the leukemic blasts. It may
be interesting to screen the whole MYH gene for
mutations in hematological malignancies in the future,
especially if increased transversions of G:C to T:A
proved to be present in leukemic blasts. Based on these
results, an association between childhood leukemias and
the MYH missense variants Tyr165Cys and Gly382Asp
was not observed. Also, these variants appear to be
absent—if not at a very low frequency—in the Turkish
population, contrary to the British population.
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